Trending NewsTrending NewsNASDAQ:DAWN Day One Biopharmaceuticals (DAWN) Stock Price, News & Analysis $6.10 +0.07 (+1.16%) Closing price 04:00 PM EasternExtended Trading$6.29 +0.19 (+3.05%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Day One Biopharmaceuticals Stock (NASDAQ:DAWN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get DAWN alerts:Sign Up Key Stats Today's Range$5.85▼$6.1250-Day Range$5.80▼$7.2352-Week Range$5.64▼$16.76Volume2.12 million shsAverage Volume2.01 million shsMarket Capitalization$624.82 millionP/E RatioN/ADividend YieldN/APrice Target$25.33Consensus RatingBuy Company Overview Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California. Read More Day One Biopharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks56th Percentile Overall ScoreDAWN MarketRank™: Day One Biopharmaceuticals scored higher than 56% of companies evaluated by MarketBeat, and ranked 495th out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingDay One Biopharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.14, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageDay One Biopharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Day One Biopharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Day One Biopharmaceuticals are expected to decrease in the coming year, from ($0.72) to ($0.97) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Day One Biopharmaceuticals is -6.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Day One Biopharmaceuticals is -6.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDay One Biopharmaceuticals has a P/B Ratio of 1.36. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted13.77% of the float of Day One Biopharmaceuticals has been sold short.Short Interest Ratio / Days to CoverDay One Biopharmaceuticals has a short interest ratio ("days to cover") of 7.5.Change versus previous monthShort interest in Day One Biopharmaceuticals has recently decreased by 12.06%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDay One Biopharmaceuticals does not currently pay a dividend.Dividend GrowthDay One Biopharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted13.77% of the float of Day One Biopharmaceuticals has been sold short.Short Interest Ratio / Days to CoverDay One Biopharmaceuticals has a short interest ratio ("days to cover") of 7.5.Change versus previous monthShort interest in Day One Biopharmaceuticals has recently decreased by 12.06%, indicating that investor sentiment is improving significantly. News and Social Media3.0 / 5News Sentiment0.48 News SentimentDay One Biopharmaceuticals has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 24 news articles for Day One Biopharmaceuticals this week, compared to 4 articles on an average week.Search InterestOnly 1 people have searched for DAWN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows4 people have added Day One Biopharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Day One Biopharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $167,298.00 in company stock.Percentage Held by InsidersOnly 6.20% of the stock of Day One Biopharmaceuticals is held by insiders.Percentage Held by Institutions87.95% of the stock of Day One Biopharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Day One Biopharmaceuticals' insider trading history. Receive DAWN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Day One Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address DAWN Stock News HeadlinesDay One Biopharmaceuticals (NASDAQ:DAWN) Price Target Lowered to $16.00 at Needham & Company LLCAugust 8 at 3:59 AM | americanbankingnews.comDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives $29.00 Consensus PT from AnalystsAugust 8 at 3:03 AM | americanbankingnews.comGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. Backed by the government but powered by private corporations, this initiative paves the way for digital dollars—programmable, trackable, and outside your control. Once embedded into apps, banks, and retail systems, opting out may no longer be possible. But there’s still time to protect your financial freedom—if you act before the system goes fully live.August 8 at 2:00 AM | Priority Gold (Ad)Day One Biopharmaceuticals (NASDAQ:DAWN) Hits New 1-Year Low After Analyst DowngradeAugust 8 at 2:19 AM | americanbankingnews.comDay One Biopharmaceuticals: Bear Case Priced In, But Bull Case Is Not (Rating Upgrade)August 7 at 11:01 PM | seekingalpha.comDay One price target lowered to $25 from $36 at H.C. WainwrightAugust 7 at 4:41 AM | msn.comDay One Biopharmaceuticals Inc (DAWN) Q2 2025 Earnings Call Highlights: Strong Revenue Growth ...August 6 at 3:55 AM | finance.yahoo.comDay One Biopharmaceuticals reports Q2 EPS (29c), consensus (34c)August 5 at 10:55 PM | msn.comSee More Headlines DAWN Stock Analysis - Frequently Asked Questions How have DAWN shares performed this year? Day One Biopharmaceuticals' stock was trading at $12.67 at the beginning of the year. Since then, DAWN shares have decreased by 51.9% and is now trading at $6.10. How were Day One Biopharmaceuticals' earnings last quarter? Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) announced its quarterly earnings data on Tuesday, August, 5th. The company reported ($0.29) EPS for the quarter, beating analysts' consensus estimates of ($0.35) by $0.06. The firm had revenue of $33.91 million for the quarter, compared to analyst estimates of $35.55 million. Day One Biopharmaceuticals had a negative net margin of 50.63% and a negative trailing twelve-month return on equity of 19.01%. Read the conference call transcript. When did Day One Biopharmaceuticals IPO? Day One Biopharmaceuticals (DAWN) raised $126 million in an initial public offering (IPO) on Thursday, May 27th 2021. The company issued 8,400,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Piper Sandler acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are Day One Biopharmaceuticals' major shareholders? Day One Biopharmaceuticals' top institutional shareholders include Geode Capital Management LLC (1.69%), Y Intercept Hong Kong Ltd (0.28%), Los Angeles Capital Management LLC (0.08%) and GC Wealth Management RIA LLC (0.08%). Insiders that own company stock include Ai Day1 Llc, Xi LP Canaan, Samuel C Blackman, Papanek Julie Grant, Julie Papanek Grant, Charles N York II, Jeremy Bender, Adam Dubow, Saira Ramasastry and Lauren Merendino. View institutional ownership trends. How do I buy shares of Day One Biopharmaceuticals? Shares of DAWN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Day One Biopharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Day One Biopharmaceuticals investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), SPDR Dow Jones Industrial Average ETF Trust (DIA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META) and Tesla (TSLA). Company Calendar Last Earnings8/05/2025Today8/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:DAWN CIK1845337 Webdayonebio.com Phone650-484-0899FaxN/AEmployees60Year FoundedN/APrice Target and Rating Average Price Target for Day One Biopharmaceuticals$25.33 High Price Target$34.00 Low Price Target$16.00 Potential Upside/Downside+315.3%Consensus RatingBuy Rating Score (0-4)3.14 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($0.95) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$95.50 million Net Margins-50.63% Pretax Margin-47.65% Return on Equity-19.01% Return on Assets-16.99% Debt Debt-to-Equity RatioN/A Current Ratio9.65 Quick Ratio10.55 Sales & Book Value Annual Sales$187.64 million Price / Sales3.30 Cash FlowN/A Price / Cash FlowN/A Book Value$4.50 per share Price / Book1.36Miscellaneous Outstanding Shares101,362,000Free Float95,078,000Market Cap$618.31 million OptionableOptionable Beta-1.26 Social Links Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NASDAQ:DAWN) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredHow high will gold surge?Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and decl...Weiss Ratings | SponsoredShocked one of my clients with thisTrump Schedules Controversial 'Market Reset' for September 30 Behind closed doors, the White House has orde...Altimetry | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | SponsoredChina's 500 Million Year AdvantageThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Day One Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Day One Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.